Chronic-pharma: New Platform for Chronic Patients Pharmacotherapy Optimization.

We describe the technological development of a web platform named CHRONIC-PHARMA that integrates three prescription support tools for patients with chronic diseases: Anticholinergic Burden Calculator (ABC), LESS-CHRON criteria and TRIGGER-CHRON. They focus on the optimization and evaluation of pharmacotherapy in patients with chronic diseases, resulting in a useful, single platform that can facilitate the review of pharmacotherapy and improve the safety of chronically ill patients. This is achieved by estimating and reducing the anticholinergic risk (ABC), detecting opportunities for deprescribing drugs and monitoring its success (LESS-CHRON criteria), as well as calculating the risk of adverse drug events (TRIGGER-CHRON). The platform is freely accessible online ( https://chronic-pharma.com/ ) as well as through a mobile application, and therefore easily accessible among the healthcare community.

[Methodological guideline for the efficacy and safety assessment of new pharmaceuticals: implementation of EUnetHTA's recommendations]. / Guía metodológica para la evaluación de la eficacia y la seguridad de nuevos fármacos: implementación de las recomendaciones de EUnetHTA.

The European network for Health Technology Assessment (EUnetHTA) is the network of public health technology assessment (HTA) agencies and entities from across the EU. In this context, the HTA Core Model®, has been developed. The Andalusian Agency for Health Technology Assessment (AETSA) is a member of the Spanish HTA Network and EUnetHTA collaboration In addition, AETSA participates in the new EUnetHTA Joint Action 3 (JA, 2016-2019). Furthermore, AETSA works on pharmaceutical assessments. Part of this work involves drafting therapeutic positioning reports (TPRs) on drugs that have recently been granted marketing authorisation, which is overseen by the Spanish Agency of Medicines and Medical Devices (AEMPS). AETSA contributes by drafting "Evidence synthesis reports: pharmaceuticals" in which a rapid comparative efficacy and safety assessment is performed for drugs for which a TPR will be created. To create this type of report, AETSA follows its own methodological guideline based on EUnetHTA guidelines and the HTA Core Model®. In this paper, the methodology that AETSA has developed to create the guideline for "Evidence synthesis reports: pharmaceuticals" is described. The structure of the report itself is also presented.

[The use and suitability of absorbent products for urinary incontinence in a primary health care district]. / Estudio sobre la utilización y adecuación de absorbentes para la incontinencia urinaria en un distrito de atención primaria.

OBJECTIVE: To calculate the use of absorbent products in patients with urinary incontinence in the Seville District Primary Health Care, and to compare the use over time, and to calculate the health costs and their variation during the period 2005-2009. METHOD: A cross-sectional and descriptive observational study was conducted on the use of urinary incontinence absorbents in the Seville District Primary Health Care, from 2005 and 2009. Patients registered as using urinary incontinence absorbents (UIA) during that period were included as the study population. MAIN VARIABLES: number of absorbent packages/number of healthcare cards by patient age and by type of contribution, and cost of UIA/number of cards by patient age and by type of social security contribution. RESULTS: There was an increase of 0.71% in the prescription of absorbents by healthcare card, patient age and by type of contribution. When comparing the different Health Areas, there was an increase of 1.06% within the Virgen del Rocío Hospital Area and an increase of 1.28% within Virgen de Macarena Hospital Area. The health expense incurred in the use of UIA during these five years was 4,100,765 €, which is an increase of 17.8%. CONCLUSIONS: There is a high increase in the use of UIA with time, causing an increase in the health costs. There was also a high frequency in the use of special beds. Therefore, it would be reasonable to train the prescribers to promote progressive and multidisciplinary treatment of UI.